Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length

This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Participants will complete questionnaires at baseline, at the end of their period during Cycle 1, and at the end of their period during Cycle 2.

Study Overview

• Status: Completed
• Conditions: Premenstrual Syndrome; Menstrual Symptoms
• Intervention / Treatment: Dietary supplement: Two Moons Seed Cycling Capsules

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89118
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be female.
• Be 18-45 years of age.
• Have experienced at least five of the following symptoms during the last three menstrual cycles:

Heavy flow Prolonged, shortened, or irregular periods Headaches or migraines Low mood Fatigue Bloating Premenstrual or menstrual cramps Breast tenderness Poor sleep Constipation or diarrhea Weight gain or fluctuations Irritability or anger Sick days or reduced social activity due to menstrual symptoms Hormonal acne

• Be generally healthy.
• Have a menstrual cycle length between 23 and 35 days.
• Track menstrual cycles and be able to predict period dates.
• Be willing to refrain from taking products, medications, or supplements targeting menstrual health during the study.

Exclusion Criteria:

• Use of hormonal contraception.
• Allergy to sesame.
• Chronic conditions that would interfere with study participation, including oncological and psychiatric disorders.
• Pregnant, breastfeeding, or trying to conceive.
• Unwillingness to follow the protocol.
• Menopause or menopausal symptoms.
• Recent or planned invasive medical procedures.
• History of substance abuse.
• Diabetes or other endocrine-related conditions.
• Current or planned participation in another research study.
• Use of hormone-modulating medications or therapies.
• Planned insertion or replacement of an IUD within 12 weeks.
• Diagnosis of endometriosis, polycystic ovary syndrome (PCOS), or adenomyosis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Seed Cycling Capsules; Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles.

Dietary supplement: Two Moons Seed Cycling Capsules; Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Participants will take two capsules with the first meal of the day according to the following schedule: Zest Capsules from Days 1-14 of the cycle, and Zen Capsules from Days 15-28 of the cycle. Participants will continue this schedule for two menstrual cycles regardless of when subsequent menstrual periods occur.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Menstrual Cramp Severity	Self-reported severity of premenstrual and menstrual cramps assessed using study questionnaires and compared between Baseline, Cycle 1, and Cycle 2.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Bloating Severity	Self-reported severity of abdominal bloating associated with the menstrual cycle assessed using study questionnaires.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Fatigue Severity	Self-reported fatigue associated with the menstrual cycle assessed using study questionnaires.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Hormonal Acne Severity	Self-reported severity and frequency of hormonal acne symptoms assessed using study questionnaires.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Mood Symptoms	Self-reported mood-related symptoms including low mood, irritability, and anger associated with the menstrual cycle.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Sleep Quality	Self-reported sleep quality and insomnia symptoms associated with the menstrual cycle.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Breast Tenderness Severity	Self-reported breast tenderness associated with the menstrual cycle.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Libido	Self-reported sex drive and libido associated with the menstrual cycle.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participant Assessment of Overall Menstrual Experience	Participant-reported assessment of the overall effect of the study product on menstrual health and menstrual cycle experience.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Satisfaction With Seed Cycling Capsules	Participant-reported satisfaction with the study product following use during the study period.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Perception of Product Effectiveness	Participant-reported perception of the effectiveness of the study product in improving menstrual symptoms.	Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

Collaborators and Investigators

• Sponsor: Superlune Inc. d/b/a Two Moons Health
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): July 8, 2025
• Primary Completion (Actual): September 27, 2025
• Study Completion (Actual): September 27, 2025

Study Registration Dates

• First Submitted: June 9, 2026
• First Submitted That Met QC Criteria: June 15, 2026
• First Posted (Actual): June 17, 2026

Study Record Updates

• Last Update Posted (Actual): June 17, 2026
• Last Update Submitted That Met QC Criteria: June 15, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Menstrual Health; Hormonal Imbalance
• Additional Relevant MeSH Terms: Pathologic Processes; Menstruation Disturbances; Pathological Conditions, Signs and Symptoms; Premenstrual Syndrome
• Other Study ID Numbers: #20756

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No